Rucaparib for Non-Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the effectiveness of rucaparib, a targeted therapy, against advanced non-small cell lung cancer with specific genetic changes in the BRCA1 or BRCA2 genes. Rucaparib blocks certain enzymes that cancer cells need to grow. Individuals with stage IV non-small cell lung cancer and specific genetic changes, such as high genomic loss of heterozygosity or harmful BRCA1/2 mutations, may qualify. Participants should not have previously used similar drugs and must be able to take pills. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to significant advancements in cancer therapy.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but you cannot receive any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment while on the study. Non-cancer-related medications, like insulin for diabetes, are allowed.
Is there any evidence suggesting that rucaparib is likely to be safe for humans?
Research has shown that rucaparib has been tested in people with certain types of cancer, providing some safety information. In one study, the most common serious side effects included low red blood cell count (anemia) in 22% of patients, low white blood cell count (lymphopenia) in 8%, tiredness in 8%, and liver issues in 5%. These findings suggest that while risks exist, many people tolerate the treatment reasonably well.
Rucaparib targets specific proteins that aid cancer cell growth. Previous tests in other cancers offer some reassurance about its safety. However, all treatments can have side effects, and individuals may experience them differently. Consulting a doctor can provide more insight into these potential effects.12345Why do researchers think this study treatment might be promising?
Unlike the standard treatments for non-small cell lung cancer, such as chemotherapy and immunotherapy, rucaparib is unique because it targets a specific enzyme involved in DNA repair. This enzyme, called PARP (poly ADP-ribose polymerase), helps cancer cells fix their damaged DNA to keep growing. By inhibiting PARP, rucaparib may prevent cancer cells from repairing themselves, potentially leading to their death. Researchers are excited about rucaparib because it offers a new way to attack cancer cells, possibly improving outcomes for patients who don't respond well to existing treatments.
What evidence suggests that rucaparib might be an effective treatment for non-small cell lung cancer?
Research has shown that rucaparib, a type of medication called a PARP inhibitor, might help treat non-small cell lung cancer (NSCLC) by stopping certain enzymes that aid cancer cell growth. Studies have found that using PARP inhibitors like rucaparib can extend the lives of some patients with NSCLC. In animal studies, rucaparib treatment reduced tumor size and slowed cancer cell growth. Some patients have experienced side effects such as anemia, which involves having too few healthy red blood cells, but these side effects are usually manageable. While more research is needed, early results are promising for rucaparib as a potential treatment for NSCLC.12467
Who Is on the Research Team?
Jonathan W Riess
Principal Investigator
SWOG Cancer Research Network
Are You a Good Fit for This Trial?
This trial is for adults with stage IV or recurrent non-small cell lung cancer that have high genomic loss of heterozygosity (LOH) or harmful BRCA1/2 mutations. Participants must be able to take oral medications, not have certain liver conditions, infections, or recent major surgeries. They should not have had prior treatment with PARP inhibitors and must agree to use effective contraception if of reproductive potential.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive rucaparib orally twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with follow-ups every 3 months for 1 year, then every 6 months for up to 3 years.
What Are the Treatments Tested in This Trial?
Interventions
- Rucaparib
Find a Clinic Near You
Who Is Running the Clinical Trial?
SWOG Cancer Research Network
Lead Sponsor
Southwest Oncology Group
Lead Sponsor
National Cancer Institute (NCI)
Collaborator